All In Biotech

Drug Trial Radar · NCT05410145

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

442

Planned (sponsor's estimate)

Start

Aug 3, 2022

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
D3 Bio (Wuxi) Co., LtdIndustry
Sponsor type
Industry
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.

Conditions

  • KRAS P.G12C

Interventions

  • D3S-001Drug

    Oral

  • PembrolizumabDrug

    Intravenous

  • CisplatinDrug

    Intravenous

  • CarboplatinDrug

    Intravenous

  • PemetrexedDrug

    Intravenous

  • CetuximabDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: From first dose until 30 days after the last dose (or specified in the protocol).
  2. Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 through Day 21. Each cycle is 21 days.

Locations

52 sites in 10 countries. Site status is shown where the registry gives one.

  • D3 Bio Investigative Site 0402

    Orange, California · Recruiting

  • D3 Bio Investigative Site 0407

    Palo Alto, California · Recruiting

  • D3 Bio Investigative Site 0404

    Denver, Colorado · Recruiting

  • D3 Bio Investigative Site 0406

    Sarasota, Florida · Recruiting

  • D3 Bio Investigative Site 0401

    Detroit, Michigan · Recruiting

  • D3 Bio Investigative Site 0405

    Nashville, Tennessee · Recruiting

  • D3 Bio Investigative Site 0403

    Houston, Texas · Recruiting

  • D3 Bio Investigative Site 0104

    Bedford Park, Australia · Recruiting

  • D3 Bio Investigative Site 0102

    Sydney, New South Wales, Australia · Recruiting

  • D3 Bio Investigative Site 0101

    Malvern, Victoria, Australia · Recruiting

  • D3 Bio Investigative Site 0105

    Melbourne, Victoria, Australia · Recruiting

  • D3 Bio Investigative Site 0103

    Nedlands, Western Australia, Australia · Recruiting

  • D3 Bio Investigative Site 0314

    Hefei, Anhui, China · Recruiting

  • D3 Bio Investigative Site 0303

    Beijing, Beijing Municipality, China · Recruiting

  • D3 Bio Investigative Site 0306

    Guangzhou, Guangdong, China · Recruiting

  • D3 Bio Investigative Site 0305

    Hangzhou, Hangzhou, China · Recruiting

  • D3 Bio Investigative Site 0307

    Harbin, Heilongjiang, China · Recruiting

  • D3 Bio Investigative Site 0309

    Wuhan, Hubei, China · Recruiting

  • D3 Bio Investigative Site 0312

    Wuhan, Hubei, China · Recruiting

  • D3 Bio Investigative Site 0315

    Changsha, Hunan, China · Recruiting

  • D3 Bio Investigative Site 0313

    Zhengzhou, Hunan, China · Recruiting

  • D3 Bio Investigative Site 0304

    Nanchang, Jiangxi, China · Recruiting

  • D3 Bio Investigative Site 0302

    Shenyang, Liaoning, China · Recruiting

  • D3 Bio Investigative Site 0310

    Jinan, Shandong, China · Recruiting

  • D3 Bio Investigative Site 0301

    Shanghai, Shanghai Municipality, China · Recruiting

  • D3 Bio Investigative Site 0308

    Shanghai, Shanghai Municipality, China · Recruiting

  • D3 Bio Investigative Site 0316

    Chengdu, Sichuan, China · Recruiting

  • D3 Bio Investigative Site 0311

    Hangzhou, Zhejiang, China · Recruiting

  • D3 Bio Investigative Site 0804

    Bordeaux, France · Recruiting

  • D3 Bio Investigative Site 0803

    Lyon, France · Recruiting

  • D3 Bio Investigative Site 0801

    Rennes, France · Recruiting

  • D3 Bio Investigative Site 0802

    Villejuif, France · Recruiting

  • D3 Bio Investigative Site 1002

    Hamburg, Germany · Recruiting

  • D3 Bio Investigative Site 1003

    Cologne, North Rhine-Westphalia, Germany · Recruiting

  • D3 Bio Investigative Site 0501

    Shatin, Hong Kong · Recruiting

  • D3 Bio Investigative Site 0905

    Candiolo, Italy · Recruiting

  • D3 Bio Investigative Site 0902

    Milan, Italy · Recruiting

  • D3 Bio Investigative Site 0904

    Naples, Italy · Recruiting

  • D3 Bio Investigative Site 0901

    Rome, Italy · Recruiting

  • D3 Bio Investigative Site 0903

    Siena, Italy · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.